Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
GALECTIN (NASDAQ: GALT) Delayed: 2.67 +0.06 (2.30%)
Previous Close $2.61    52 Week High $3.05 
Open $2.61    52 Week Low $0.49 
Day High $2.76    P/E N/A 
Day Low $2.58    EPS $-1.32 
Volume 282,138